Using the TIMER database, TMEM119 was found to be upregulated in STAD, as well as in other cancers, such as hepatocellular carcinoma, head and neck squamous cell carcinoma, and cholangiocarcinoma (Figure 1(a); P < 0.05). Here, TMEM119 is linked to cholangiocarcinoma.